Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10037502HBVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS10035945HBVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30078847HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30087830HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30087535HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30085016HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30058438HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS30058439HIVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TVIS20044022HPVENSG00000114054.14protein_codingPCCBNoNo5096P05166
TCGA Plot Options
Drug Information
GenePCCB
DrugBank IDDB00121
Drug NameBiotin
Target IDBE0000544
UniProt IDP05166
Regulation Typecofactor
PubMed IDs17139284; 17016423; 15623830; 9311592; 14997352; 16772434
CitationsOverington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Vlasova TI, Stratton SL, Wells AM, Mock NI, Mock DM: Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood. J Nutr. 2005 Jan;135(1):42-7.@@Cherbonnel-Lasserre CL, Linares-Cruz G, Rigaut JP, Sabatier L, Dutrillaux B: Strong decrease in biotin content may correlate with metabolic alterations in colorectal adenocarcinoma. Int J Cancer. 1997 Sep 4;72(5):768-75.@@Ishii M, Chuakrut S, Arai H, Igarashi Y: Occurrence, biochemistry and possible biotechnological application of the 3-hydroxypropionate cycle. Appl Microbiol Biotechnol. 2004 Jun;64(5):605-10. Epub 2004 Feb 28.@@Hassan YI, Zempleni J: Epigenetic regulation of chromatin structure and gene function by biotin. J Nutr. 2006 Jul;136(7):1763-5.
GroupsApproved; Investigational; Nutraceutical
Direct ClassificationBiotin and derivatives
SMILES[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2
PathwaysMitochondrial Complex II Deficiency; 3-Methylglutaconic Aciduria Type III; 2-Ketoglutarate Dehydrogenase Complex Deficiency; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Isovaleric Aciduria; Pyruvate Carboxylase Deficiency; Warburg Effect; Isobutyryl-CoA Dehydrogenase Deficiency; Biotin Metabolism; Fructose-1,6-diphosphatase Deficiency; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Propionic Acidemia; Transfer of Acetyl Groups into Mitochondria; Malonic Aciduria; 2-Hydroxyglutric Aciduria (D and L Form); 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Congenital Lactic Acidosis; 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency; Fumarase Deficiency; Succinic Semialdehyde Dehydrogenase Deficiency; Alanine Metabolism; Methylmalonic Aciduria; 3-Methylglutaconic Aciduria Type IV; Lactic Acidemia; Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease; Primary Hyperoxaluria Type I; Triosephosphate Isomerase; The Oncogenic Action of 2-Hydroxyglutarate; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease
PharmGKBPA448625
ChEMBLCHEMBL857